Deutsche Bank Ag\ Caladrius Biosciences, Inc. Transaction History

Deutsche Bank Ag\

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$1.21 - $3.47 $12,091 - $34,675	-9,993 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.02 - $2.85 $41,616 - $58,715	-20,602 Reduced 67.34%	9,993 $25,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $2.99 $65,916 - $88,779	-29,692 Reduced 49.25%	30,595 $79,000
Q2 2019 Aug 14, 2019	BUY	$2.25 - $3.6 $34,724 - $55,558	15,433 Added 34.41%	60,287 $137,000
Q1 2019 May 15, 2019	SELL	$3.48 - $5.32 $21,426 - $32,755	-6,157 Reduced 12.07%	44,854 $162,000
Q4 2018 Feb 14, 2019	SELL	$3.49 - $5.77 $21,987 - $36,351	-6,300 Reduced 10.99%	51,011 $181,000
Q3 2018 Nov 14, 2018	BUY	$4.85 - $6.5 $235,763 - $315,971	48,611 Added 558.75%	57,311 $338,000
Q2 2018 Aug 14, 2018	BUY	$3.8 - $8.64 $33,060 - $75,168	8,700 New	8,700 $56,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.